Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) have demonstrated the ability to improve myocardial function following transplantation into an ischemic heart; however, the functional benefits are transient possibly due to poor cell retention. A diagnostic technique that could visualize transplanted hESC-CMs could help to optimize stem cell delivery techniques. Thus, the purpose of this study was to develop a labeling technique for hESCs and hESC-CMs with the FDA-approved contrast agent indocyanine green (ICG) for optical imaging (OI). hESCs were labeled with 0.5, 1.0, 2.0, and 2.5 mg/ml of ICG for 30, 45, and 60 min at 37°C. Longitudinal OI studies were performed with both hESCs and hESC-CMs. The expression of surface proteins was assessed with immunofluorescent staining. hESCs labeled with 2 mg ICG/ml for 60 min achieved maximum fluorescence. Longitudinal studies revealed that the fluorescent signal was equivalent to controls at 120 h postlabeling. The fluorescence signal of hESCs and hESC-CMs at 1, 24, and 48 h was significantly higher compared to precontrast data (p < 0.05). Immunocytochemistry revealed retention of cell-specific surface and nuclear markers postlabeling. These data demonstrate that hESCs and hESC-CMs labeled with ICG show a significant fluorescence up to 48 h and can be visualized with OI. The labeling procedure does not impair the viability or functional integrity of the cells. The technique may be useful for assessing different delivery routes in order to improve the engraftment of transplanted hESC-CMs or other stem cell progenitors.
INTRODUCTION
cells (hMSC), hESC-CMs have a distinct advantage because their in vitro differentiation model closely resembles in vivo cardiac development at a structural and elec-Stem cell therapies hold unprecedented potential to provide therapeutics for a wide variety of diseases. Due trophysiological level. Few studies, however, currently demonstrate this potential for hMSC (4, 11, 14, 19) . to the limited mitotic abilities of cells in many organs and thus a limited regeneration capacity, injury resulting A major challenge for successful hESC-derived myocardial regeneration is the development of an efficient from disease or trauma often leads to irreversible cell damage. Human embryonic stem cells (hESCs) have the delivery technique. Previous studies have shown poor outcomes of hESC-CM delivery, such that the majority unique ability to regenerate into cells of almost all human tissues (2, 5, 21) . hESC-CMs are a particularly prom-of the injected cells are either washed away to extra cardiac organs or die soon after injection (7, 17) . More spe-ising source of therapeutics for myocardial regeneration following cardiac ischemia. When compared to cardiac cifically, the present cell survival rate of hESC-CM transplants in cardiac infarcts is bleak, with only 10% of the progenitors derived from human mesenchymal stem 56 BODDINGTON ET AL. cells surviving the injection. This poor survival rate is stock solutions at concentrations of 0.5, 1, 2, and 2.5 mg/ml. thought to be the primary reason behind the limited benefits observed in cardiac function following hESC-CM-Culture of Undifferentiated hESCs based therapy (7) . A diagnostic technique that could directly visualize the transplanted hESC-CM in vivo is All studies were in accordance with and approved by our institution's Committee on Human Research. For needed in order to help direct and optimize stem cell delivery techniques and confirm successful stem cell de-conduction of the described experiments, HSF-6 hESCs (UC06, a federal line/NIH approved) were kept in an position into the myocardium (20) .
Among various available imaging techniques, optical undifferentiated and pluripotent state, cultured on gelatin-coated (0.1% gel) 10-cm (Falcon) petri dishes, and imaging (OI) has the advantage of being quick, inexpensive, easy to perform, noninvasive, and does not involve plated on irradiated mouse embryonic fibroblasts (MEFs ϳ800,000 cells/plate). The feeder cells were mitotically ionizing radiation. The first clinical OI scanners have recently entered clinical applications and pilot studies inactivated using a cesium source gamma irradiator (3000 rad for 15 min). Culture medium [Knockout Se-show promising results for investigations of breast tissue in patients (13) .
rum Replacement (KSR) media] contained: Knockout DMEM (Invitrogen, Carlsbad, CA, USA) supplemented In order to track hESCs and/or their progeny with OI, cells must be labeled with an exogenous or endogenous with 20% KSR (Invitrogen), 1% nonessential amino acids (Invitrogen), 1 mM L-glutamine (Invitrogen), 0.1 marker. While many investigators have focused on bioluminescence OI techniques (e.g., firefly luciferase) for mM mercaptoethanol (Sigma), and 4 ng/ml human basic FGF (Invitrogen). Cells were maintained at 37°C in 5% in vivo stem cell tracking, this technique has little clinical relevance because it involves the introduction of CO 2 and split by manual dissection at a ratio of 1:3 approximately every 4 days. hESCs were grown until 10-nonhuman virus substrates into the cells of interest (Dluciferin), which alters the host's DNA permanently (7). cm petri dishes were 80% confluent. Three days prior to labeling experiments the hESCs were dissected with the Exogenous fluorescent markers represent a potentially clinically applicable alternative to firefly luciferase. In-EZ tool (Invitrogen) to ensure that the colonies were divided into homogeneous subcolonies. Following dis-docyanine green (ICG) is an exogenous fluorescent marker with a favorable near-infrared (NIR) absorption section, an equal amount of cell solution was transferred to six-well plates (Corning Inc. VWR Int., West Chester, and emission spectrum (600-950 nm) and is FDA approved for investigations of cardiac perfusion in patients PA, USA) that were pregelatinized with 0.1% gel and plated with ϳ100,000 feeders. Once colonies formed, (23) .
The purpose of this study was to establish a labeling roughly 3-4 days later, the cells were ready to be labeled. technique of hESCs and hESC-CMs with ICG for subsequent OI. The major goal of this investigation was to Optimization of hESC Labeling develop an ICG-labeling protocol, which should provide maximal fluorescence of labeled hESCs and hESC-CMs hESCs were incubated with increasing concentrations of 0.5, 1.0, 1.5, 2.0, and 2.5 mg ICG/ml for either 30, on OI scans and, at the same time, preserve cell viability and expression of appropriate surface markers. If suc-45, or 60 min in standard cell culture conditions. The stock cell labeling solution was added to cell culture cessful, this technique would be in principle readily applicable for monitoring stem cell-based therapies, partic-dishes (60 µl/ml). Following incubation the cells were trypisinized (0.25% trypsin), washed three times in PBS, ularly new injection techniques. resuspended in 10 ml of prewarmed KSR, and trans-MATERIALS AND METHODS ferred to gelatinized-coated (0.1% gel) 10-cm petri Contrast Agent dishes. hESCs were separated from feeders after an incubation of 60 min at 37°C/5% CO 2 , at which time the ICG is an FDA-approved, hydrophilic, anionic, tricarbocyanine NIR dye with a molecular weight of feeder cells adhered tightly to the plate, while the labeled hESCs only adhered weakly. The hESCs were 774.97 Da. The structure of ICG is composed of two polycyclic moieties connected by a carbon chain. ICG collected by pipetting and were transferred to a 15-ml centrifuge tube (26) . hESCs were then counted and shows an absorbance peak at 780 nm and an emission peak at 830 nm (22). The ICG solution used in this study transferred into microcentrifuge tubes for OI (VWR Int.) where they contained 300,000 cells/1 ml KSR media. was prepared by dissolving ICG powder (laser grade I-25; Sigma-Aldrich Co., St. Louis, MO) in 20% dimethyl Cardiomyocyte Differentiation sulfoxide (DMSO, 99.9%, purchased from Sigma-Aldrich Co.) and 80% Dulbecco's modified Eagles me-hESCs were allowed to spontaneously differentiate into beating cardiomyocytes using established methods dium (D-MEM High Glucose; D5648) with resulting (16) . Briefly, embryoid bodies (EBs) were first produced were resuspended in 1 ml of fresh KSR or CM media and imaged until the fluorescent signal matched that of in six-well low attachment plates. On day 7 EBs were transferred to a standard six-well plate precoated with the nonlabeled control cells. All experiments were performed in triplicate ( Fig. 1 ). 0.1% gelatin. Cardiomyocyte media was similar to the KSR used in the undifferentiated culture, but lacked
Optical Imaging Data Analysis bFGF and contained 20% defined FBS (Hyclone) in-For quantitative analyses of OI data, regions of interstead of 20% KSR. est (ROI) were placed on each ICG test sample (micro-Beating cardiomyocytes (CMs) were labeled on day centrifuge tube). Quantitative measures of fluorescence 25 with ICG under previously optimized conditions that intensity of labeled cells in test tubes were normalized were established using the hESCs. CMs were grown in to units of average efficiency, displayed in the same six-well plates that were precoated with 0.10% gelatin.
scale of fluorescent intensity, and analyzed using the Following labeling beating CMs were dissected out with Living Image 2.5 software (Xenogen, Alameda, CA). a P-100 micropipette and transferred to a 15-ml conical The unit of "efficiency" represents the fractional ratio of tube. The cell suspension was then enzymatically disfluorescent-emitted photons per incident excitation phopersed using TrypLE (GIBCO, 12604) for 5 min at 37°C ton (Xenogen). and then neutralized with CM media containing 20% FBS. Cells were allowed to suspend by gravity and were Statistical Analysis washed with phosphate-buffered saline (PBS) three
Means and SDs were used to describe the variation times and were then resuspended in fresh CM media for in fluorescent signal over time and viability for the folimaging.
lowing groups: 1) fluorescent signal for hESCs compared to nonlabeled controls, 2) fluorescent signal for Optical Imaging CMs compared to nonlabeled controls, 3) fluorescent In vitro fluorescence imaging was performed with an signal for hESCs compared to CMs, and 4) viability of IVIS 50 Imaging System (Xenogen, Alameda, CA). The CMs compared to nonlabeled controls. The multivariate optical imager is an integrated fluorescence system analysis of variance (MANOVA) was used to describe (400-900 nm) that is composed of a light-tight specithe variation in fluorescent signal and viability for men chamber (dark box) and a 0.5-inch charge-coupled hESCs compared to nonlabeled controls for the various device (CCD) camera. To minimize electronic backlabeling protocols (various ICG concentrations and incuground and maximize sensitivity, the CCD camera is bation times). Multiple comparison p-values were deterthermoelectrically cooled to −70°C.
mined by the Tukey-Kramer test. All analyses were per-All in vitro experimental samples were imaged in 1 formed by SAS software (SAS V9.3; Cary, NC, USA). ml of KSR or CM media in microcentrifuge tubes (VWR Int.). All images were acquired using the filter Cell Viability Testing setting preset for ICG with a background wavelength at Trypan blue tests were performed on all cells before 665-695 nm, an excitation wavelength at 710-760 nm, and after the labeling procedure to verify viability. Cells and an emission wavelength set at 810-875 nm. Consiswere counted in a hemocytometer and then underwent tent illumination parameters were used for all NIR fluosubsequent optical imaging studies. rescent acquisitions. For all experiments, the field of view (FOV) was set at 7, exposure time was 2 s, f/stop Immunohistochemistry was 2, lamp voltage was set to "high" and binning was Analysis of hESC Pluripotency Postlabeling. To enkept on medium. Following acquisition, all images were sure that the hESCs retained marker expression patterns normalized to units of average efficiency, displayed in characteristic of undifferentiated hESCs postlabeling, the same scale of fluorescent intensity, and analyzed usthe cells were analyzed using immunofluorescence teching the Living Image 2.5 software (Xenogen, Alameda, niques followed by fluorescent microscopy. hESC un-CA).
derwent labeling under the optimized conditions as de-Optimization of the Cell Labeling Protocol. hESCs scribed above. The ICG-labeled hESCs and unlabeled labeled with different ICG concentrations and incubacontrols were manually dissected out, washed three tion times underwent OI directly after the labeling protimes, and replated onto 24-well plates that were pregecess.
latinized with 0.1% gel and contained 20,000 irradiated feeder cells per well. After colony formation occurred Longitudinal Follow-up Studies. hESCs and hESC-CMs were labeled with the optical labeling protocol, de-(approximately 4 days later) the cells were incubated with primary antibodies according to the manufacturer's termined based on experiments from the above protocol, and in separate tubes 100,000 hESCs or hESC-CMs instructions (ES Cell Marker Sample Kit protocol; Chemicon, Billerica, MA) followed by incubation with Primary antibodies were added to chamber slides in a total of 200 µl/well of antibody buffer and incubated the secondary antibody Alexa Fluor 488 Goat antimouse IgG. Confocal images were acquired using a overnight at 4°C. Primary antibodies were Troponin T (Thermo Scientific, MS-295-PO), GATA4 (Abcam, Leica microscope. ab61170), Connexin43 (Millipore, AB1728), Alexa Fluor 488 Phalloidin (Invitrogen, A12379), Islet1 (De-Assessment of Cardiomyocyte Protein Expression Postlabeling. Following labeling with ICG, the beating velopmental Studies Hybridoma Bank), Lin28 (R&D Systems, AF3757), Wnt-8A (R&D Systems, AF2248), CM areas were dissected out with a P-100 micropipette and transferred to a 15-ml conical tube. The cell suspen-TBX5 (GenWay, 18-003-42369), SMA. All were used at 1:100. The next day cells were washed three times for sion was then enzymatically dispersed using TrypLE (GIBCO, 12604) for 5 min at 37°C and then neutralized 1 min each in washing buffer 2 (0.03% Triton X-100 in PBS at pH 7.4) followed by an additional wash in PBS with CM media containing 20% FBS. Cells were allowed to settle by gravity and were then resuspended in for 1 min. Cells were incubated with proper secondary antibodies in 1× PBS. Secondary antibodies used were fresh CM media. ROC inhibitor was added at a concentration of 10 µM (EMD: y-27632) to prevent apoptosis.
Alexa Fluor anti-rabbit 555 (Molecular Probes, A21429), Alexa Fluor anti-mouse IgG 488 (Molecular Cells were plated at a low density on pregelatinizedcoated wells of Lab-Tek II eight-well glass chamber Probes, A11029), and Alexa Fluor anti-goat 555 (Invitrogen Molecular Probes, A21431). All were used at slide system and incubated for 24 h. Cells were fixed using 4% paraformaldyhyde for 15 min. Cells were 1:500. Slides were placed in humidifying trays/covered and left on benchtop for 1-2 h. Cells were washed in washed two times for 1 min with PBS followed by washing three times for 1 min each with washing buffer washing buffer 2 for 1 min and then washed again in PBS for 1 min, postfixed with 4% PFA for 1 min, fol-1 (0.10% Triton X-100 in PBS at pH 7.4). Cells were blocked with 10% PBS, 0.10% Triton X-100, 5% nor-lowed by washing with PBS for 1 min. Samples were combined with VECTASHIELD mounting medium mal goat serum, and in PBS for 1 h at room temperature.
containing DAPI (Vector Laboratories Inc., H-1500) and
Twelve days after induction of hESC differentiation as described above (16) , beating cardiomyocytes ap-wells were sealed with coverslips. Samples were then imaged using a Zeiss AxioObserver Z1 microscope.
peared. Longitudinal studies of CMs, labeled on day 25 with 2.0 mg ICG/ml for 60 min, revealed similar fluo-RESULTS rescence signal kinetics compared to labeled hESCs (Fig. 4) . The cells' fluorescence signal was significantly Optical Imaging elevated at 1, 24, and 48 h (p < 0.05), but showed no Optimization of hESC Labeling Protocol. Labeling significant difference compared to baseline data at 120 of hESCs with varying concentrations and incubation h postlabeling (p > 0.05). times showed a maximal fluorescence signal with the Fluorescence. The fluorescence signal of CMs was combination of the 60-min incubation time and an ICG significantly higher compared to the fluorescence signal concentration of 2.0 mg/ml (Fig. 2) . The average fluoof hESCs at 1 h (p < 0.0001), 48 h (p < 0.05), 72 h (p < rescence signal was significantly higher with the 60-min 0.01), and 96 h (p < 0.001) while there was no statistiincubation time compared to lower incubation times cally significant difference in signal at 24 h postlabeling (p < 0.0001), and also significantly higher with the ICG (Fig. 5 ). concentration of 2.0 mg/ml than lower or higher concentrations (p < 0.0001).
Viability Testing Longitudinal OI Studies. Labeling of hESCs with
Trypan blue exclusion testing showed no significant ICG at a concentration of 2.0 mg/ml after a 60-min incudifference in viability between labeled hESCs or labeled bation time revealed that the fluorescent signal slowly CMs compared to unlabeled controls. All groups exhibdecreased over time, compatible with slow release of the ited viabilities greater than 88%, which were not significontrast agent from the cells. The signal decreased by cantly different between experimental groups (p > 0.05) 50% within 48 h postlabeling and was equivalent to con- (Fig. 2) . trols at 120 h postlabeling (Fig. 3) . The fluorescence Immunocytochemistry signal at 1, 24, and 48 h was significantly higher compared to precontrast data (p < 0.05). The signal at 120 h Analysis of hESC Pluripotency. Fluorescent microscopy experiments following immunohistochemistry re-postlabeling was not significantly different from baseline (p > 0.05).
vealed that ICG-labeled and unlabeled HSF-6 cells expressed the surface antigens SSEA-3, SSEA-4, TRA-ocyte function. The ICG-labeled hESCs and cardiomyocytes can be detected up to 48 h postlabeling with 1-60, and TRA-1-81 and did not express SSEA-1 (Fig.  6) . These expression patterns are consistent with undif-optical imaging.
Our study is novel with regard to two aspects. 1) To ferentiated hESCs or "pluripotent" stem cells. Furthermore, there were no observed morphologic abnormali-the best of our knowledge, this is the first study that utilized the FDA-approved fluorochrome ICG for the la-ties of labeled hESCs (colonies had clearly defined borders and the cells within each colony were homoge-beling of hESCs and hESC-derived CMs. Murine ESCderived hepatocytes have been previously labeled with nously sized) compared to unlabeled controls.
ICG and adult mesenchymal stem cells have been previously labeled with other organic fluorescent markers, Retention of Cardiomyocyte Protein Expression Postlabeling. The presence of cardiac-specific proteins was such as PKH67, PKH26 (1), GFP (6), Gadophrin-2 and luc (27), but this is the first study that has utilized ICG studied using immunocytochemistry. Figure 7 shows positive staining for Connexin43, Lin28, Troponin T, for the purpose of tracking hESCs and hESC-derived CMs. 2) Previous studies used a stereomicroscope for Actin + Lin28, Wnt8a, TBX5, GATA4, and Islet1. The staining patterns recapitulate previous publications on the visualization of ICG-labeled cells in vitro (28) , while the current study is the first that utilized ICG labeling the location of the targeted proteins (Fig. 7) . There was no difference in antigen expression patterns between la-for stem cell depiction with optical imaging. While the ICG-labeling technique is in principle beled and unlabeled CMs.
ready to be translated to the in vivo arena, there are DISCUSSION specific obstacles that need to be addressed for successful in vivo applications. One example of this is the cur-The results of this study indicate that hESCs and hESC-CMs can be labeled by simple incubation with the rent poor survival rate of transplanted stem cells, which could be improved by optimizing stem cell delivery FDA-approved fluorescent marker ICG without impairing the cells viability, hESCs pluripotency, or cardiomy-techniques, such as delivery mode (direct myocardial in- jection vs. coronary vessel delivery), catheter types, nee-other cell types. Conversely, the present study aimed to load high quantities of ICG into hESCs and hESC-CMs dle size, timing of cell delivery with regard to an ischemic event, and optimization of scaffolds that can in order to achieve the highest possible fluorescent signal without affecting the cells viability or function. "anchor" the cells to the area of interest.
The described data confirm previous studies about Our studies are in accordance with previous reports by other investigators who found that ICG does not alter the feasibility of cell labeling with ICG (3,12,28). ICG labeling of murine ESC-derived hepatocytes was origi-the viability or function of the labeled cells. We found an unaltered protein expression of ICG-labeled hESCs nally optimized by Yamada et al. and subsequent studies have followed the original labeling protocol, which in-and hESC-CMs. Other investigators reported an unaltered morphology, tissue integration, function, and im-cluded a 15-min incubation with ICG at a concentration of 1.0 mg/ml (3, 12, 28) . Our optimized labeling protocol munoreactivity of ICG-labeled hepatocytes compared to unlabeled controls in vivo (28) . for human hESCs and hESC-CMs included longer incubation periods and higher ICG concentrations compared Our ICG-labeled hESC-CMs demonstrated a stronger fluorescence signal compared to ICG-labeled hESCs at to Yamada et al.'s (28) protocol. These discrepancies are most likely due to the difference in goals of the two all time points of observation. This phenomenon can be explained by the increased network of gap junctions in studies. Yamada et al. was optimizing a protocol to distinguish hepatocytes from the rest of the EBs based on the CMs, which permit the transfer of molecules under 1,000 Da from cell to cell (18) . Additionally, the in-the fact that hepatocytes have a higher affinity for the dye and internalize ICG more rapidly compared to the creased signal seen in the CMs is due to their relatively larger diameter of 20-30 µm compared to undifferenti-route of cell delivery to myocardium in a clinical setting is cell administration through an intracoronary injection. ated hESCs with a diameter of about 10 µm (22) (Fig. 6) .
We observed an excretion of ICG from the hESCs Limited benefits from this approach have prompted investigators to assess different delivery methods, such as and hESC-CMs within 120 h. While this limits the potential for extensive long-term-follow-up studies, the direct intramyocardial injections. A recent study investigated the distribution patterns of transplanted bone mar-rapid excretion of ICG suggests a safe elimination. Of note, the cellular excretion of ICG varies with cell type.
row stem cells transfected with firefly luciferase following three delivery methods: intra-aortic, intravenous, and Hepatocyte-like cells (HLCs) excreted ICG even faster, within 20 h postlabeling (12) .
intramyocardial. Within 48 h of delivery, the large majority of the implanted cells localized to extracardiac or-The mechanism by which ICG is taken up into cells and excreted has been studied extensively and has been gans with all of these delivery methods. Interestingly, this study also revealed the importance of the timing of shown to follow an active saturable carrier-mediated transport process, according to the Michaelis-Menten delivery with regard to the ischemic event. When cells were injected into an acute infarct there was a 50% sur-equation (8, 9) . The release of ICG from cells is due to cytoplasmic and biliary excretion mechanisms. Further-vival rate at 2 h, but improved retention was observed when cells were injected into a more mature infarct (15) . more, excretion relies on the membrane potential-dependent transport system established by an ATP-utilizing These results confirm the critical need of a cell tracking technique in the early phase after delivery of therapeutic pump (24).
Major efforts have recently focused on improving cells, which would be possible with our ICG-labeling technique. cell engraftment following a myocardial infarct (MI) by assessing different modes of delivery (25) . One possible
The ICG-labeling technique is advantageous over other techniques being developed because it is cost ef-CONCLUSIONS fective, technically straightforward, and rapid (<2 h).
In summary, the derived data establish an optimized The most notable advantage of the ICG-labeling techtechnique for depiction of the labeled cells with optical nique compared to others in the field, namely labeling imaging and illustrates the feasibility of hESC-based lawith iron oxide-based nanoparticles for MR imaging, is beling with the FDA-approved fluorescent dye ICG. the magnitudes increased sensitivity that one achieves Other potential applications of the ICG-labeling techwith OI. While MRI has the advantage of high anatominique include, but are not limited to, investigations of cal resolution, it provides limited sensitivity. Single cell other stem cell lineages and progenitors, such as neural sensitivity is especially important in the field of stem precursors, chondrocytes, osteoblasts, and neutrophils. cell research due to the unpredictable migrational dy-ACKNOWLEDGMENTS: This study was supported by a renamics of the cells, even after local injections. While cells could be detected with OI for at least 48 h; how-
